

SHI Board Communiqué – July 2023

The SHI Board met on 18th July 2023 and discussed the following matters:

Board Chair – topics for discussion

- The Chair opened the meeting and welcomed Martina Otten to the meeting who will be Acting CEO whilst David Malone is on annual leave.

Practice management modernisation project

- The CEO provided an update on the practice modernisation project.
- Work has commenced to explore potential approaches and providers with the aim to commence a baseline assessment that will provide recommendations for areas of improvement and potential digital solutions.
- The Board is very supportive of this project as it aligns with SHI's aspiration to be efficient, effective, and serve patients.

Draft Budget 2023-24

- The CEO briefed the Board on the draft budget for the 2023-24 financial year. It is a responsible budget with a small operating surplus and pay increases for all staff, based on achievable revenue targets and well-considered forecasts of expenses. The budget will resource the continued delivery of SHI's world-class dermatological clinical services, a highly valued and comprehensive education program, and SHI's centre of excellence in dermatology-related research including the Australasian Dermatology Registry.
- FARM Chair Jim Power noted that the budget was circulated and approved by the FARM Committee out of session with a recommendation to the Board for approval.
- The Board approved the budget for the 2023-24 financial year and thanked the Leadership and Finance teams for their work on developing the budget and noted that the revenue targets were carefully considered and achievable.

Operational updates

- The progress on the financial sustainability plan is encouraging.
- The Board was pleased to hear about the continued increase in surgery activity.
- The work on the strategic review of clinics is continuing and the CEO thanked A/Prof Patrick Mahar for his support.
- Feedback rating for SHI education events continues to be high, with SHI recently holding the first face-to-face Clinical Meeting on behalf of the Victorian Faculty after 3 ½ years.
- Three new clinical trials are now open for recruitment and two new interventional clinical trials have been awarded to SHI.

Approved by A/Prof Rosemary Nixon AM, Chair of the SHI Board